长光华芯在 2025 年上半年的经营情况如何？ Q&A 长光华芯 20250709 摘要 长光华芯 2025 年上半年 100G EML 产品实现量产，Q3 接到 CW 订单， 预计下半年量产突破，光通信板块全年营收预计数千万元，明年有望翻 倍。威斯科进展稍慢，预计年底量产。 激光雷达行业受益于降价趋势，更多车型应用，数量增加但整体营收变 化不明显。未来元器件成本将降低，显著改善营收。主要客户为下游光 模块厂商，数据中心终端订单来自国内，海外公司陆续对接。 100G EML 产品已验证一年左右，目前批量供货，良率爬坡中。与海外 相比，良率优势暂不明显，但随着规模扩大和技术成熟，将逐步提升良 率并优化成本结构。产品价格低于海外市场。 长光华芯产能充足，但利用率不足。100G EML 用于 400G/800G 光模 块，4W EML 用于 800G/1.6T 光模块，终端客户主要是国内数据中心， 下游客户为国内厂商。 2025 年三款 100G EML 产品预计营收数千万元，2026 年订单量预计 成倍增长，达 1-2 亿元。拓展海外市场策略包括绑定下游光模块厂商和 直接对接海外客户。 2025 年上半年，长光华 ...

COMBINING TO CURE ® Forward-Looking Statements/Safe Harbor Arcus is at the forefront of designing combination therapies, with best-in-class potential, in the relentless pursuit of cures for cancer. Forward Looking Statements Safe Harbor: This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in t ...

21世纪经济报道记者 张赛男 上海报道 近年来，随着中国市场对数据传输带宽和算力的需求持续增长，光通信行业进入了快速发展期。随着技 术创新的不断突破，国内光芯片产业链已覆盖设计、外延、制造、封测全环节，纯粹的III-V族DFB、 EML、APD等激光芯片基本实现自主可控。本次参会企业均在持续进行研发投入，通过原创技术为我 国光芯片产业的自主可控打下坚实基础。 德科立董事长桂桑分享了公司在光通信产业中的技术突破与市场布局。近年来，德科立通过自主研发， 在薄膜铌酸锂芯片和O-Band半导体光放大芯片等领域逐步突破了核心技术的瓶颈，为国内光通信产业 提供了坚强的技术支持。特别是在算力中心的光交换技术领域，德科立的硅基光波导高速光交换机已经 获得了海外样品订单，为国产芯片的全球布局打下了基础。 长光华芯董事长闵大勇表示，面对持续爆发式增长的市场需求和更高性能芯片的要求，公司利用IDM平 台优势持续投入研发，根据市场需求推出"国产替代"的高性能光通信芯片产品，成功实现了EML、 VCSEL、CW Laser等关键光通信芯片的国产化。公司的100G EML已实现量产出货 200G EML已经开始 送样，100G VCSE ...

攻坚技术壁垒自主可控加速推进 光芯片被誉为"光通信的心脏"。近年来，随着中国市场对数据传输带宽和算力的需求持续增长，光通信 行业进入了快速发展期。 德科立董事长桂桑表示，近年来，公司通过自主研发，在薄膜铌酸锂芯片和O-Band半导体光放大芯片 等领域逐步突破了核心技术的瓶颈，为国内光通信产业提供了技术支持。特别是在算力中心的光交换技 术领域，德科立的硅基光波导高速光交换机已获得了海外样品订单。 上交所近日举办科创板新质生产力行业沙龙第二季第5期"光芯片中国算力新'燃点'"，邀请四家光芯片 企业，与多家证券公司、基金管理公司共同探讨国产化进程中的技术攻坚、产业链协同和全球化布局等 关键问题，旨在为行业发展指引方向，推动中国光芯片产业迈向更高水平。 程硕表示，光通信行业技术演进迅速，技术迭代存在周期性，企业唯有持续加码研发、动态调整产能策 略，方能规避阶段性产能错配风险。源杰科技重点布局高功率CW激光器等产品，提升产品附加值。 深化全球布局引领国际产业新局 随着全球光芯片市场竞争加剧，国际巨头并购整合进程提速，中国光芯片企业如何提升全球竞争力，实 现从"国产替代"向"全球竞合"跨越也是此次沙龙的热议话题。 长光华 ...

证券研究报告：电子 | 公司点评报告 股票投资评级 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 源杰科技(688498) 数据中心 CW 硅光光源、EML 产品加速放量 l 投资要点 买入 |维持 个股表现 2024-06 2024-09 2024-11 2025-01 2025-04 2025-06 -45% -36% -27% -18% -9% 0% 9% 18% 27% 36% 45% 源杰科技 电子 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 166.50 | | --- | --- | | 总股本/流通股本（亿股）0.86 | / 0.60 | | 总市值/流通市值（亿元）143 | / 100 | | 52 周内最高/最低价 | 182.99 / 79.20 | | 资产负债率(%) | 3.5% | | 市盈率 | -2,378.57 | | 第一大股东 | ZHANG XINGANG | 研究所 光模块市场快速扩张，拉动 CW 硅光光源芯片、EML 芯片等需求。 随着人工智能的快速发展，模型性能提 ...

Core Insights - Novo Nordisk announced new data from the phase III FRONTIER clinical program for its investigational candidate, Mim8, as a prophylaxis treatment for hemophilia A, showing promising results in switching from Roche's Hemlibra treatment [1][2][4] Group 1: Study Results - The phase IIIb FRONTIER5 study indicated that switching from Hemlibra to Mim8 was well-tolerated with no safety issues reported in adults and adolescents, regardless of inhibitor status [2][4][7] - Patient-reported outcomes showed a strong preference for the Mim8 pen-injector, which was easier to use compared to the Hemlibra injection system, suggesting high potential for patient compliance [2][4] - Mim8 maintained clotting activity without adverse events or antibody detection, with no thromboembolic events or treatment-related adverse events leading to discontinuation [4][7] Group 2: Treatment Administration - Patients received their first Mim8 maintenance dose on the scheduled day of their next Hemlibra dose, with options for weekly, biweekly, or monthly dosing [6] - Steady-state levels of Mim8 were achieved by week 16, and Roche's Hemlibra was fully cleared by week 26, indicating a smooth transition [6] Group 3: Future Outlook - Novo Nordisk plans to submit Mim8 for regulatory review in 2025, with additional data from the phase III FRONTIER program expected in 2025 and 2026 [8] - Currently, Mim8 is not approved by regulatory authorities anywhere in the world [8] Group 4: Industry Context - Hemophilia A affects approximately 1.1 million people globally, with up to 30% of those with severe hemophilia A developing inhibitors that reduce the effectiveness of replacement therapies [9]

Japan Equity Research June 20, 2025 Pharmaceutical Sector Data Book – Valuation, Product Sales Trend Biotechnology & Pharmaceuticals/ Medical Technologies & Services Seiji Wakao, Ph.D. AC seiji.wakao@jpmorgan.com (81-3) 6736-8612 | | | | | P/E(x) | | | | | | P/B(x) | | | | | | EV/EBITDA(x) | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | FY25E | FY26E | FY27E | FY28E | FY29E | FY35E | FY25E | FY26E | FY27E | FY28E | FY29E ...

Core Insights - Roche announced positive phase I/II data for NXT007, a next-generation bispecific antibody for haemophilia A, supporting its progression to phase III clinical development [1][2] - NXT007 demonstrated a tolerable safety profile with no thromboembolic events reported, indicating its potential for haemostatic normalization in patients without factor VIII inhibitors [1][4] Company Overview - Roche has over 25 years of experience in developing medicines for blood diseases and is committed to advancing care for patients with haemophilia A [9] - The company aims to provide innovative treatment options, including NXT007, to enhance therapeutic choices and reduce treatment burdens for patients [2][6] Clinical Development - NXT007 is currently undergoing a robust clinical development program, with ongoing phase I/II trials and additional phase II data expected later this year [3] - Three phase III studies are planned for 2026, including a head-to-head study with Hemlibra, Roche's existing prophylactic treatment for haemophilia A [3][4] Product Details - NXT007 is engineered to optimize factor VIII-mimetic activity and enhance potency, efficacy, and administration convenience, aiming for sustained elevated bleed protection [6][5] - The clinical trials for NXT007 involve participants aged 12 to 65, with no treated bleeds observed in the highest dose cohorts [4][7] Market Context - Haemophilia A affects approximately 900,000 people globally, leading to significant health concerns due to uncontrolled bleeding [8][7] - The development of inhibitors to factor VIII replacement therapies presents a serious complication, highlighting the need for innovative treatments like NXT007 [8]

27 May 2025 | 8:44AM CST YJ Semitech (688498.SS): TechNet China 2025: CW laser ramp remains the primary driver for 2025; Sell | Technet China | | --- | We hosted YJ Semitech at GS TechNet China 2025 conference. Key investors' focus during the meeting was on the company's CW laser ramp outlook, margin dynamics, and scope for EML expansion. The company echoed the supply tightness in laser chips (EML and CW lasers) and maintained that its CW laser will see meaningful shipment ramp in coming quarters. In the me ...

27 May 2025 | 8:44AM CST YJ Semitech (688498.SS): TechNet China 2025: CW laser ramp remains the primary driver for 2025; Sell We hosted YJ Semitech at GS TechNet China 2025 conference. Key investors' focus during the meeting was on the company's CW laser ramp outlook, margin dynamics, and scope for EML expansion. The company echoed the supply tightness in laser chips (EML and CW lasers) and maintained that its CW laser will see meaningful shipment ramp in coming quarters. In the meantime, the company has pl ...